Year/N° pts / Median follow up (months) / Control arm schedules (n° pts) /
exp. arm schedules (n° pts) / N° cycles control/exp arms / Cumulative dose of anthracyclines cotrol/exp arms (mg/m2) / Reason for exclusion
Bear 2003 / III/ 2003 / 2411 / nd / · AC60 q21 (804 pts)®surgery
· AC60 q21 → D 100 mg/m2 q21 (805 pts)®surgery
· AC60 q21 ®surgery® D 100 mg/m2 q21 (802 pts) / 4/4-4 / A 240 / Neoadj trial
Mansi 2010 / III/ 2010 / 363 / 32 / · AC60 q21 (180 pts)®surgery
· AD50 q21 (133 pts)®surgery / 6/6 / A360
A300 / Neoadj trial
Dieras 2004 / III /2004 / 200 / 31 / · AP60 q21 (133 pts)®surgery
· AC60 q21 (67 pts)® surgery / 4/4 / A 240 / Neoadj trial
Smith 2002 / III / 2002 / 162 / nd / · CVAP50 q21 ( 162 pts) : if CR or PR ® CVAP50 q21
· (52 pts) or DOC 100 mg/m2 q 21 (52 pts) ®surgery
· If Non R ® DOC 100 mg/m2 q 21 ( 55 pts) ® surgery / 4® 4 / 4 / 4 / A 200 / Neoadj trial
Elling 2003 / II / 2003 / 60 / nd / · E VNB90 q 21 (15 pts)
· E VNB90 q 21 ® P 175 mg/m2 (15 pts)
· EC 90 q 21 ( 15 pts )
· EC 90 q 21 ® P 175 mg/m2 (15 pts) / 4 / 4-4 / 4/
4-4 / E 360 / Did not report cardiovascular toxicity, leukemias and deaths
P: Paclitaxel; D: Docetaxel; A: Doxorubicin; E: Epirubicin; FEC: 5Fluorouracil + Epirubicin + Cyclophosphamide; CMF: Cyclophosphamide + Methotrexate + 5Fluorouracil; VNB: Vinorelbine; C: Cyclophosphamid; 5FU: 5Fluorouracil; q: every. Pts: patients; Ref: reference; N°: number
Table 2: main exlcuded studies